Cargando…
24-h Efficacy of Glaucoma Treatment Options
Current management of glaucoma entails the medical, laser, or surgical reduction of intraocular pressure (IOP) to a predetermined level of target IOP, which is commensurate with either stability or delayed progression of visual loss. In the published literature, the hypothesis is often made that IOP...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846688/ https://www.ncbi.nlm.nih.gov/pubmed/26909513 http://dx.doi.org/10.1007/s12325-016-0302-0 |
_version_ | 1782429081050021888 |
---|---|
author | Konstas, Anastasios G. P. Quaranta, Luciano Bozkurt, Banu Katsanos, Andreas Garcia-Feijoo, Julian Rossetti, Luca Shaarawy, Tarek Pfeiffer, Norbert Miglior, Stefano |
author_facet | Konstas, Anastasios G. P. Quaranta, Luciano Bozkurt, Banu Katsanos, Andreas Garcia-Feijoo, Julian Rossetti, Luca Shaarawy, Tarek Pfeiffer, Norbert Miglior, Stefano |
author_sort | Konstas, Anastasios G. P. |
collection | PubMed |
description | Current management of glaucoma entails the medical, laser, or surgical reduction of intraocular pressure (IOP) to a predetermined level of target IOP, which is commensurate with either stability or delayed progression of visual loss. In the published literature, the hypothesis is often made that IOP control implies a single IOP measurement over time. Although the follow-up of glaucoma patients with single IOP measurements is quick and convenient, such measurements often do not adequately reflect the untreated IOP characteristics, or indeed the quality of treated IOP control during the 24-h cycle. Since glaucoma is a 24-h disease and the damaging effect of elevated IOP is continuous, it is logical that we should aim to understand the efficacy of all treatment options throughout the 24-h period. This article first reviews the concept and value of diurnal and 24-h IOP monitoring. It then critically evaluates selected available evidence on the 24-h efficacy of medical, laser and surgical therapy options. During the past decade several controlled trials have significantly enhanced our understanding on the 24-h efficacy of all glaucoma therapy options. Nevertheless, more long-term evidence is needed to better evaluate the 24-h efficacy of glaucoma therapy and the precise impact of IOP characteristics on glaucomatous progression and visual prognosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12325-016-0302-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4846688 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-48466882016-05-21 24-h Efficacy of Glaucoma Treatment Options Konstas, Anastasios G. P. Quaranta, Luciano Bozkurt, Banu Katsanos, Andreas Garcia-Feijoo, Julian Rossetti, Luca Shaarawy, Tarek Pfeiffer, Norbert Miglior, Stefano Adv Ther Review Current management of glaucoma entails the medical, laser, or surgical reduction of intraocular pressure (IOP) to a predetermined level of target IOP, which is commensurate with either stability or delayed progression of visual loss. In the published literature, the hypothesis is often made that IOP control implies a single IOP measurement over time. Although the follow-up of glaucoma patients with single IOP measurements is quick and convenient, such measurements often do not adequately reflect the untreated IOP characteristics, or indeed the quality of treated IOP control during the 24-h cycle. Since glaucoma is a 24-h disease and the damaging effect of elevated IOP is continuous, it is logical that we should aim to understand the efficacy of all treatment options throughout the 24-h period. This article first reviews the concept and value of diurnal and 24-h IOP monitoring. It then critically evaluates selected available evidence on the 24-h efficacy of medical, laser and surgical therapy options. During the past decade several controlled trials have significantly enhanced our understanding on the 24-h efficacy of all glaucoma therapy options. Nevertheless, more long-term evidence is needed to better evaluate the 24-h efficacy of glaucoma therapy and the precise impact of IOP characteristics on glaucomatous progression and visual prognosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12325-016-0302-0) contains supplementary material, which is available to authorized users. Springer Healthcare 2016-02-24 2016 /pmc/articles/PMC4846688/ /pubmed/26909513 http://dx.doi.org/10.1007/s12325-016-0302-0 Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Konstas, Anastasios G. P. Quaranta, Luciano Bozkurt, Banu Katsanos, Andreas Garcia-Feijoo, Julian Rossetti, Luca Shaarawy, Tarek Pfeiffer, Norbert Miglior, Stefano 24-h Efficacy of Glaucoma Treatment Options |
title | 24-h Efficacy of Glaucoma Treatment Options |
title_full | 24-h Efficacy of Glaucoma Treatment Options |
title_fullStr | 24-h Efficacy of Glaucoma Treatment Options |
title_full_unstemmed | 24-h Efficacy of Glaucoma Treatment Options |
title_short | 24-h Efficacy of Glaucoma Treatment Options |
title_sort | 24-h efficacy of glaucoma treatment options |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846688/ https://www.ncbi.nlm.nih.gov/pubmed/26909513 http://dx.doi.org/10.1007/s12325-016-0302-0 |
work_keys_str_mv | AT konstasanastasiosgp 24hefficacyofglaucomatreatmentoptions AT quarantaluciano 24hefficacyofglaucomatreatmentoptions AT bozkurtbanu 24hefficacyofglaucomatreatmentoptions AT katsanosandreas 24hefficacyofglaucomatreatmentoptions AT garciafeijoojulian 24hefficacyofglaucomatreatmentoptions AT rossettiluca 24hefficacyofglaucomatreatmentoptions AT shaarawytarek 24hefficacyofglaucomatreatmentoptions AT pfeiffernorbert 24hefficacyofglaucomatreatmentoptions AT migliorstefano 24hefficacyofglaucomatreatmentoptions |